Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy

AIDS

Volumn 15, Issue 1, 2001, Pages 33-45

  Goebel, Frank D ^a,g   Hemmer, Robert ^b   Schmit, Jean Claude ^b   Bogner, Johannes R ^a   De Clercq, Erik ^c   Witvrouw, Myriam ^c   Pannecouque, Christophe ^c   Valeyev, Rustem ^d   Vandevelde, Michel ^e   Margery, Hélène ^e   Tassignon, Jean Pierre ^f  

^a UNIVERSITY OF MUNICH   (Germany)

^b Infectious Diseases Department   (Luxembourg)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d PSI Pharma Support AG   (Switzerland)

^e Hubriphar SA   (Belgium)

^f Tassignon and Partners SA   (Belgium)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZOFORMAMIDE; UNCLASSIFIED DRUG; UREA DERIVATIVE; ZINC FINGER PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MAXIMUM ALLOWABLE CONCENTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; AZO COMPOUNDS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; HIV-1; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 0035808584     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101050-00007     Document Type: Article

References (44)

1. ADA, a potential anti-HIV drug
2. ADA, a potential anti-HIV drug
3. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein
4. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins
5. Virus-encoded zinc fingers as targets for antiviral chemotherapy
6. Azodicarbonamide inhibits T cell responses in vitro and in vivo
7. The fate of inhaled azodicarbonamide in rats
8. Azodicarbonamide
9. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
10. Mechanism of FK506-induced glucose intolerance in rats
11. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets
12. Differential phosphorylation of azothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells
13. The effect of dideoxycytidine on lymphocyte subpopulations in nonhuman primates
14. T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation
15. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes
16. Studies of N-hydroxy-N'-aminoguanidine derivatives by nitrogen 15 nuclear magnetic resonance spectroscopy and as ribonucleotide reductase inhibitors
17. Properties of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of mammalian ribonucleotide reductase
18. Hydroxyurea
19. Divergent antihuman immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells
20. Efficacy of saquinavir in patients with advanced HIV infection
21. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
22. Virological efficacy and drug levels of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy
23. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS
24. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party
25. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals
26. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients
27. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus
28. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
29. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial
30. Safety and activity of saquinavir in HIV infection
31. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
32. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study
33. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection
34. Adding saquinavir to stavudine in patients with advanced HIV-1 infection
35. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex
36. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients
37. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT)
38. Studies of zidovudine in combination with didanosine and zalcitabine
39. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial
40. Treatment of human immunodeficiency virus infection with hydroxyurea: Virologic and clinical evaluation
41. Treatment with ziduvodine and lamivudine combination in HIV(+) patients: A preliminary report